Author:
Fineman Mark S.,McAlindon Timothy E.,Lattermann Christian,Swearingen Christopher J.,Kennedy Sarah,Lopez Victor A.,Simsek Ismail,Tambiah Jeyanesh R. S.,Yazici Yusuf
Publisher
Springer Science and Business Media LLC
Subject
Immunology and Allergy,Rheumatology
Reference12 articles.
1. Wallace IJ, Worthington S, Felson DT, et al. Knee osteoarthritis has doubled in prevalence since the mid-20th century. Proc Natl Acad Sci U S A. 2017;114:9332–6.
2. Richard MJ, Driban JB, McAlindon TE. Pharmaceutical treatment of osteoarthritis. Osteoarthr Cartil. 2023;31:458–66.
3. Yazici Y, McAlindon TE, Gibofsky A, et al. A phase 2b randomized trial of lorecivivint, a novel intra-articular CLK2/DYRK1A inhibitor and Wnt pathway modulator for knee osteoarthritis. Osteoarthr Cartil. 2021;29:654–66.
4. Yazici Y, McAlindon TE, Fleischmann R, et al. A novel Wnt pathway inhibitor, SM04690, for the treatment of moderate to severe osteoarthritis of the knee: results of a 24-week, randomized, controlled, phase 1 study. Osteoarthr Cartil. 2017;25:1598–606.
5. International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use. Integrated addendum to ICH E6(R1): guideline for good clinical practice E6(R2). Federal Register Vol. 83, No. 41, p. 8882–3; 2016. https://www.ich.org/. Accessed 15 June 2023.